Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Xtacy Therapeutics (DE:TT5)
FRANKFURT:TT5
RESEARCH TOOLSreports
Xtacy Therapeutics (TT5) Stock Price & Analysis
0 Followers
TT5 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.01 - €0.12
Previous Close€0.01
Volume0.00
Average Volume (3M)199.00
Market Cap
€1.34M
Enterprise Value€1.35M
Total Cash (Recent Filing)C$0.00
Total Debt (Recent Filing)C$15.97K
Price to Earnings (P/E)N/A
Beta33.53
Next Earnings
May 30, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding49,214,971
10 Day Avg. Volume131
30 Day Avg. Volume199
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-3.45
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)4.70
P/FCF Ratio4.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Xtacy Therapeutics News
PremiumCompany Announcements
Xtacy Therapeutics Resolves Filing Delay
PremiumCompany Announcements
Xtacy Therapeutics Extends Management Trading Ban
PremiumCompany Announcements
Xtacy Therapeutics Reports on MCTO Status
PremiumCompany Announcements
Xtacy Therapeutics Reports Filing Delay and MCTO
PremiumPre-Earnings
Is TESS a Buy, Before Earnings?
TT5 FAQ
What was Xtacy Therapeutics’s price range in the past 12 months?
Xtacy Therapeutics lowest stock price was €0.01 and its highest was €0.12 in the past 12 months.
What is Xtacy Therapeutics’s market cap?
Currently, no data Available
When is Xtacy Therapeutics’s upcoming earnings report date?
Xtacy Therapeutics’s upcoming earnings report date is May 30, 2024 which is in 26 days.
How were Xtacy Therapeutics’s earnings last quarter?
Currently, no data Available
Is Xtacy Therapeutics overvalued?
According to Wall Street analysts Xtacy Therapeutics’s price is currently Overvalued.
Does Xtacy Therapeutics pay dividends?
Xtacy Therapeutics does not currently pay dividends.
What is Xtacy Therapeutics’s EPS estimate?
Xtacy Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xtacy Therapeutics have?
Currently, no data Available
What happened to Xtacy Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Xtacy Therapeutics?
Currently, no hedge funds are holding shares in DE:TT5
---
Xtacy Therapeutics Stock Smart Score
Company Description
Xtacy Therapeutics
Redfund Capital Corp is a debt financing company. The company provides debt financing facility to help companies build their valuation and get to the next level in its financing cycle without giving away equity prematurely in their growth cycle. It is focusing on providing finance to medical cannabis, hemp, and CBD-related, healthcare-related target companies.
---
Technical Analysis
Aclaris Therapeutics
―
Spyre Therapeutics
―
Agile Therapeutics
―
Akari Therapeutics
―
Xtacy Therapeutics
―
---